IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Open accessThe DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant of PD-1-directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related signatures correlating with clinical benefit using a learn-and-confirm paradigm based on data from different clinical studies of pembrolizumab, starting with a small pilot of 19 melanoma patients and eventually defining a pan-tumor T cell-inflamed GEP in 220 patients with 9 cancers. Predictive value was independently confirmed and compared with that of PD-L1 immunohistochemistry in 96 patients with head and neck squamous cell carcinoma. The T cell-inflamed GEP contained IFN-γ-responsive genes related to antigen presentation, chemokine expression, cytotoxic activity, and adaptive immune resistance, and these features were necessary, but not always sufficient, for clinical benefit. The T cell-inflamed GEP has been developed into a clinical-grade assay that is currently being evaluated in ongoing pembrolizumab trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of tumor inflammation, as assessed by the presence of type I/II IFN signaling and infiltrating effector T cells, is associated with an improved response to checkpoint immunotherapy (8–11,13).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Defects associated with this pathway and its downstream effectors have shown both negative and positive correlations with response to ICB, suggesting a dual role for this pathway in tumor immunity (Ayers et al., 2017; Gao et al., 2016).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several gene signatures capturing the inflamed components of the TME have been associated with a favourable response to ICIs69,72,78–81, but none has been clinically validated thus far.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [81]
The cited source says what the claim attributes to it.
In the citing paper
“Interferon (IFN) signaling through the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway plays a prominent role in tumor immunity.”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Ayers et al., 2017
The cited source says what the claim attributes to it.
In the citing paper
“In the clinic, a strong IFN-γ signature has been identified as a useful predictor and indicator of response in anti-PD-1-treated patients across various cancer indications (75,92,93).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [93]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Regularization and Variable Selection Via the Elastic Net
Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“org Volume 127 Number 8 August 2017 Introduction Cancer cells have the ability to adapt to and avoid host immune checkpoints and surveillance as a means to promote their continued survival (1, 2).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“These data extend the observations of previous reports showing that CD8+ T lymphocytes and T cell active chemokines and T cell counterinhibitory molecules such as PD-1/PD-L1 and IDO1 are coregulated within tumors (4, 15, 21, 22) and confirm that response to anti–PD-1 blockade occurs primarily in patients with such a p…”
ResultSelf-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“Newer genomic technologies can be used to evaluate complexities of tumor and Recently, increased PD-L1 expression on the surface of tumor cells has been identified as an important determinant of response to immune therapies targeting the PD-1 axis (16).”
BackgroundSelf-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · cited 2×
“Likewise, these data provide a much higher level of statistical validation across multiple tumor types than has previously been reported for single genes associated with the IFN-γ signaling pathway and response to PD-1 blockade (17), indicating that integrated multigene signatures might represent more robust predictiv…”
Background
Cited by
Items 501–600 of 1,011
Shahbandi, A., Chiu, F.-Y., Ungerleider, N. A., Kvadas, R., Mheidly, Z., Sun, M. J. S., Tian, D., Waizman, D. A., Anderson, A. Y., Machado, H. L., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00466-y · Cited by 83
Immune escape and resistance to immunotherapy in mismatch repair deficient tumors
Mestrallet, G., Brown, M., Bozkus, C. C., & Bhardwaj, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210164 · Cited by 97
Pender, A., Titmuss, E., Pleasance, E., Fan, K. Y., Pearson, H., Brown, S. D., Grisdale, C. J., Topham, J. T., Shen, Y., Bonakdar, M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1163 · Cited by 96
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00632 · Cited by 86
Rožman, P. J., & Švajger, U. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.04.001 · Cited by 95
Bridge, J. A., Lee, J., DAUD, A. I., Wells, J. W., & Bluestone, J. A. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00351 · Cited by 89
Kirchhammer, N., Trefny, M. P., Natoli, M., Brücher, D., Smith, S. N., Werner, F., Koch, V., Schreiner, D., Bartoszek, E. M., Buchi, M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm9043 · Cited by 93
IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma
Reijers, I. L. M., Rao, D., Versluis, J. M., Menzies, A. M., Dimitriadis, P., Wouters, M. W. J. M., Spillane, A. J., Klop, W. M. C., Broeks, A., Bosch, L. J. W., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221952 · Cited by 91
“In our previous OpACIN-neo trial testing different dosing schedules of neoadjuvant ipilimumab + nivolumab in stage III melanoma, we identified the 10-gene IFN-γ signature (Ayers et al., 2017) as a predictive baseline biomarker for pathologic response (Rozeman et al.”
MethodYu, H., Chen, Z., Ballman, K. V., Watson, M. A., Govindan, R., Lanc, I., Beer, D. G., Bueno, R., Chirieac, L. R., Chui, M. H., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.006 · Cited by 92
Wang, S., Zhang, J., He, Z., Wu, K., & Liu, X. (2019) · International Journal of Cancer · doi:10.1002/ijc.32327 · Cited by 92
High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot
Keam, S. P., Halse, H. M., Nguyen, T. Q., Wang, M., Losio, N. V. K., Mitchell, C., Caramia, F., Byrne, D. J., Haupt, S., Ryland, G. L., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000792 · Cited by 88
“15 This signature identifies the presence of an inflamed immune infiltrate in tissues associated with activation of the IFN γ pathway, antigen presentation and T cell activation—and classifies tissues into three broad categories: high, intermediate, or low.”
Arneson, D. V., Yang, X., & Wang, K. (2020) · Communications Biology · doi:10.1038/s42003-020-01146-2 · Cited by 109
Rubio-Pérez, C., Planas‐Rigol, E., Trincado, J. L., Bonfill‐Teixidor, E., Arias, A., Marchese, D., Moutinho, C., Serna, G., Pedrosa, L., Iurlaro, R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21789-x · Cited by 88
Mak, T. K., Li, X., Huang, H., Wu, K., Huang, Z., He, Y., & Zhang, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.951214 · Cited by 97
“edu/) but obtained the T-cell-inflamed signature (TIS) score calculating the average value of a log2-scale normalized expression in the 18 signature genes (29).”
MethodBae, J., Liu, L., Moore, C., Hsu, E. J., Zhang, A., Ren, Z., Sun, Z., Wang, X., Zhu, J., Shen, J., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-01024-5 · Cited by 91
Translation of AI into oncology clinical practice
El Naqa, I., Karolak, A., Luo, Y., Folio, L., Tarhini, A. A., Rollison, D., & Parodi, K. (2023) · Oncogene · doi:10.1038/s41388-023-02826-z · Cited by 81
Saha, D., Martuza, R. L., & Rabkin, S. D. (2018) · Immunotherapy · doi:10.2217/imt-2018-0009 · Cited by 89
Treg Destabilization and Reprogramming: Implications for Cancer Immunotherapy
Munn, D. H., Sharma, M. D., & Johnson, T. S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1351 · Cited by 84
William, W. N., Zhao, X., Bianchi, J. J., Lin, H. Y., Cheng, P., Lee, J. J., Carter, H. K., Alexandrov, L. B., Abraham, J. P., Spetzler, D. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022655118 · Cited by 93
Emens, L. A., Adams, S., Cimino‐Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., Kalinsky, K. M., McArthur, H. L., Mittendorf, E. A., Nanda, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002597 · Cited by 91
Yap, T. A., Gainor, J. F., Callahan, M. K., Falchook, G. S., Pachynski, R. K., LoRusso, P. M., Kummar, S., Gibney, G. T., Burris, H. A., Tykodi, S. S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4256 · Cited by 85
Self-citationLin, Y., Peng, L., Dong, L., Liu, D., Ma, J., Lin, J., Chen, X., Lin, P., Song, G., Zhang, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1640 · Cited by 90
Luo, Z., Mei, J., Wang, X., Wang, R., He, Z., Geffen, Y., Sun, X., Zhang, X., Xu, J., Wan, R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114697 · Cited by 90
Nederlof, I., Isaeva, O. I., de Graaf, M., Gielen, R., Bakker, N. A. M., Rolfes, A. L., Garner, H., Boeckx, B., Traets, J. J. H., Mandjes, I. A. M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03249-3 · Cited by 94
Bretz, A. C., Parnitzke, U., Kronthaler, K., Dreker, T., Bartz, R., Hermann, F., Ammendola, A., Wulff, T., & Hamm, S. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0745-3 · Cited by 83
Cariani, E., & Missale, G. (2019) · Liver International · doi:10.1111/liv.14192 · Cited by 90
Yeong, J., Suteja, L., Simoni, Y., Lau, K. W., Tan, A. C., Li, H. H., Lim, S., Loh, J. H., Wee, F. Y. T., Nerurkar, S. N., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.016 · Cited by 83
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
Diab, A. K., Tykodi, S. S., Daniels, G. A., Maio, M., Curti, B. D., Lewis, K. D., Jang, S., Kalinka‐Warzocha, E., Puzanov, I. J., Spira, A. I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00675 · Cited by 86
Wen, T., Barham, W. J., Li, Y., Zhang, H., Gicobi, J. K., Hirdler, J. B., Liu, X., Ham, H., Martinez, K., Lucien, F., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0539 · Cited by 90
Mok, T. S. K., Lopes, G., Cho, B. C., Kowalski, D. M., Kasahara, K., Wu, Y.-L. L. C., de Castro, G., Turna, H. Z., Cristescu, R., Aurora-Garg, D., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.01.011 · Cited by 88
Self-citationWu, W., Liu, Y., Zeng, S., Han, Y., & Shen, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01166-3 · Cited by 88
Zhang, H., Zhang, N., Wu, W., Zhou, R., Li, S., Wang, Z., Dai, Z., Zhang, L., Liu, Z., Zhang, J., et al. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac386 · Cited by 93
Melero, I., Tanos, T., Bustamante, M., Sanmamed, M. F., Calvo, E., Moreno, I., Moreno, V., Hernández‐Guerrero, T., Martinez‐García, M., Rodríguez‐Vida, A., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abp9229 · Cited by 91
VDAC2 loss elicits tumour destruction and inflammation for cancer therapy
Yuan, S., Sun, R., Shi, H., Chapman, N. M., Hu, H., Guy, C. S., Rankin, S. L., Anil, K. C., Palacios, G., Meng, X., et al. (2025) · Nature · doi:10.1038/s41586-025-08732-6 · Cited by 95
Molecular Basis of Tumor Heterogeneity in Endometrial Carcinosarcoma
Leskelä, S., Perez‐Mies, B., Rosa-Rosa, J. M., Cristóbal, E., Biscuola, M., Palacios‐Berraquero, M. L., Ong, S., Matías‐Guiu, X., & Palacios, J. (2019) · Cancers · doi:10.3390/cancers11070964 · Cited by 91
Poudel, P., Nyamundanda, G., Patil, Y., Cheang, M. C. U., & Sadanandam, A. (2019) · npj Breast Cancer · doi:10.1038/s41523-019-0116-8 · Cited by 90
Targeted and novel therapy in advanced gastric cancer
Selim, J. H., Shaheen, S., Sheu, W.-C., & Hsueh, C.-T. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0149-6 · Cited by 87
Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers
Lü, Z., Peng, Z., Liu, C. X., Wang, Z., Wang, Y., Jiao, X., Li, J., & Shen, L. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100041 · Cited by 91
Siu, L. L., Wang, D., Hilton, J., Geva, R., Rasco, D., Perets, R., Abraham, A. K., Wilson, D. C., Markensohn, J. F., Lunceford, J., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2160 · Cited by 85
Self-citationRen, J., Li, N., Pei, S., Lian, Y., Li, L., Peng, Y., Liu, Q., Guo, J., Wang, X., Han, Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153167 · Cited by 89
Cappuyns, S., Piqué‐Gili, M., Esteban-Fabró, R., Philips, G., Balaseviciute, U., Pinyol, R., Gris‐Oliver, A., Vandecaveye, V., Abril‐Fornaguera, J., Montironi, C., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.12.016 · Cited by 106
Gallotta, M., Assi, H. H., Degagné, É., Kannan, S. K., Coffman, R. L., & Guiducci, C. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0729 · Cited by 87
The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer
Tang, Y., Zhang, P., Wang, Y., Wang, J., Su, M., Wang, Y., Zhou, L., Zhou, J., Xiong, W., Zeng, Z., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00604 · Cited by 87
Jansen, Y. J. L., Krüse, V., Corthals, J., Schats, K., van Dam, P., Seremet, T., Heirman, C., Brochez, L., Kockx, M. M., Thielemans, K., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02618-4 · Cited by 80
Bao, R., Stapor, D. C., & Luke, J. J. (2020) · Genome Medicine · doi:10.1186/s13073-020-00787-6 · Cited by 88
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
Qu, J., Mei, Q., Liu, L., Cheng, T., Wang, P., Chen, L., & Zhou, J. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835921992968 · Cited by 86
Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
Cristescu, R., Nebozhyn, M., Zhang, C., Albright, A. V., Kobie, J., Huang, L., Zhao, Q., Wang, A., Ma, H., Cao, Z. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3329 · Cited by 82
Self-citationSvensson‐Arvelund, J., Cuadrado‐Castano, S., Pantsulaia, G., Kim, K., Aleynick, M., Hammerich, L., Upadhyay, R., Yellin, M. J., Marsh, H. C., Oreper, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34791-8 · Cited by 84
Sullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L. A., Gajewski, T. F., Gastman, B., Lawson, D. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0362-6 · Cited by 81
Immunotherapy for advanced thyroid cancers — rationale, current advances and future strategies
French, J. D. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0398-9 · Cited by 85
Immune Aging and Immunotherapy in Cancer
Kaiser, M., Semeraro, M. D., Herrmann, M., Absenger, G., Gerger, A., & Renner, W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22137016 · Cited by 84
Peng, S., Chen, S., Hu, W., Mei, J., Zeng, X., Su, T., Wang, W., Chen, Z., Xiao, H., Zhou, Q., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0931 · Cited by 82
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 81
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 84
Identification of Distinct Immune Subtypes in Colorectal Cancer Based on the Stromal Compartment
Shen, R., Li, P., Li, B., Zhang, B., Feng, L., & Cheng, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01497 · Cited by 114
You, L., Zhao, Y., Kuča, K., Wang, X., Olekšák, P., Chrienová, Ž., Nepovimová, E., Jacevic, V. M., Wu, Q., & Wu, W. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03030-2 · Cited by 81
PD-L1 lncRNA splice isoform promotes lung adenocarcinoma progression via enhancing c-Myc activity
Qu, S., Jiao, Z., Lu, G., Yao, B., Wang, T., Rong, W., Xu, J., Fan, T., Sun, X., Yang, R., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02331-0 · Cited by 84
Melanoma dedifferentiation induced by IFN-γ epigenetic remodeling in response to anti–PD-1 therapy
Kim, Y. J., Sheu, K. M., Tsoi, J., Abril-Rodríguez, G., Medina, E., Grasso, C. S., Torrejon, D. Y., Champhekar, A. S., Litchfield, K., Swanton, C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145859 · Cited by 83
Self-citationPereira, B., Chen, C. T., Goyal, L., Walmsley, C. S., Pinto, C. J., Baiev, I., Allen, R., Henderson, L. E., Saha, S. K., Reyes, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23394-4 · Cited by 82
Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment
Yang, L., Ning, Q., & Tang, S. (2022) · Journal of Immunology Research · doi:10.1155/2022/8052212 · Cited by 98
Wu, Z., Uhl, B., Gires, O., & Reichel, C. A. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00915-5 · Cited by 86
PD-1/PD-L1 Axis in Lung Cancer
Santini, F. C., & Hellmann, M. D. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000300 · Cited by 83
Sonpavde, G., Manitz, J., Gao, C., Tayama, D., Kaiser, C., Hennessy, D., Makari, D., Gupta, A. K., Abdullah, S. E., Niegisch, G., et al. (2020) · The Journal of Urology · doi:10.1097/ju.0000000000001199 · Cited by 78
Kauffmann-Guerrero, D. E., Kahnert, K., Kiefl, R., Sellmer, L., Walter, J., Behr, J., & Tufman, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-90397-y · Cited by 84
Zhou, H., Wang, Y., Xu, H., Shen, X., Zhang, T., Zhou, X. M., Zeng, Y., Li, K., Zhang, L., Zhu, H., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci161065 · Cited by 77
Immune landscape of breast tumors with low and intermediate estrogen receptor expression
Voorwerk, L., Sanders, J., Keusters, M. S., Balduzzi, S., Cornelissen, S., Duijst, M., Lips, E. H., Sonke, G. S., Linn, S. C., Horlings, H. M., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00543-0 · Cited by 85
Computational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 85
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 87
du Rusquec, P., de Calbiac, O., Robert, M., Campone, M., & Frenel, J. (2019) · Cancer Management and Research · doi:10.2147/cmar.s151023 · Cited by 83
Targeting cancer stem cells in the clinic: Current status and perspectives
Annett, S., & Robson, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.001 · Cited by 70
Immune oncology, immune responsiveness and the theory of everything
Turan, T., Kannan, D., Patel, M., Matthew Barnes, J., Tanlimco, S. G., Lu, R., Halliwill, K., Kongpachith, S., Kline, D. E., Hendrickx, W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0355-5 · Cited by 75
Fröhlich, A., Loick, S., Bawden, E., Fietz, S., Dietrich, J., Diekmann, E., Saavedra, G., Fröhlich, H., Niebel, D., Sirokay, J. D., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102647 · Cited by 82
Principe, N., Kidman, J., Goh, S., Tilsed, C. M., Fisher, S. A., Fear, V. S., Forbes, C. A., Zemek, R. M., Chopra, A., Watson, M. W., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584423 · Cited by 93
“ICT drives dynamic changes in CTL frequency (7, 9), phenotype (10–12), proliferation (13, 14), and cytotoxic function (6, 15).”
BackgroundCheng, J., Luo, W., Sun, C., Jin, Z., Zeng, X., Alexander, P. B., Gong, Z., Xia, X., Ding, X., Xu, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abc7609 · Cited by 78
Self-citationWatson, R. A., Tong, O., Cooper, R. A., Taylor, C. A., Sharma, P. K., Aires, A. V. D. L., Mahé, E. A., Ruffieux, H., Nassiri, I., Middleton, M. R., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj8825 · Cited by 79
Shi, R., Wang, X., Wu, Y. F., Xu, B., Zhao, T., Trapp, C., Wang, X., Unger, K., Zhou, C., Lu, S., et al. (2022) · Theranostics · doi:10.2139/ssrn.4062750 · Cited by 83
Chow, R. D.-W., Michaels, T., Bellone, S., Hartwich, T. M. P., Bonazzoli, E., Iwasaki, A., Song, E., & Santin, A. D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0686 · Cited by 85
Zhao, S., Chen, D.-P., Fu, T., Yang, J., Ma, D., Zhu, X.-Z., Wang, X.-X., Jiao, Y., Jin, X., Xiao, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42504-y · Cited by 94
Cross-tissue multicellular coordination and its rewiring in cancer
Shi, Q., Chen, Y., Li, Y., Qin, S., Yang, Y., Gao, Y., Zhu, L., Wang, D., & Zhang, Z. (2025) · Nature · doi:10.1038/s41586-025-09053-4 · Cited by 93
Correlates of immune and clinical activity of novel cancer vaccines
van der Burg, S. H. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.04.001 · Cited by 77
“Also, the presence of a type 1 inflamed immune signature is important for responsiveness [50].”
BackgroundGuillebon, É. D., Dardenne, A., Saldmann, A., Séguier, S., Tran, T., Paolini, L., Lebbé, C., & Tartour, É. (2020) · International Journal of Cancer · doi:10.1002/ijc.32889 · Cited by 78
Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis
Kato, S., Weng, Q. Y., Insco, M. L., Chen, K. Y., Muralidhar, S., Poźniak, J., Diaz, J. M. S., Drier, Y., Nguyen, N. T., Lo, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0532 · Cited by 79
Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade
Gstalder, C., Liu, D., Miao, D., Lutterbach, B. A., DeVine, A. L., Lin, C., Shettigar, M., Pancholi, P., Buchbinder, E. I., Carter, S. L., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1416 · Cited by 78
Krishnamoorthy, M., Lenehan, J. G., & Vareki, S. M. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa216 · Cited by 76
Gallic acid induces T-helper-1-like T reg cells and strengthens immune checkpoint blockade efficacy
Deng, B., Yang, B., Chen, J., Wang, S., Zhang, W., Guo, Y., Han, Y., Li, H., Dang, Y., Yuan, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004037 · Cited by 88
Xu, K., Ma, J., Hall, S. R. R., Peng, R., Yang, H., & Yao, F. (2023) · Theranostics · doi:10.7150/thno.80184 · Cited by 82
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Davar, D., Morrison, R. M., Dzutsev, A., Karunamurthy, A. D., Chauvin, J.-M., Amatore, F., Deutsch, J. S., das Neves, R. X., Rodrigues, R. R., McCulloch, J. A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.007 · Cited by 80
Duarte, J. D. G., Parakh, S., Andrews, M. C., Woods, K., Pasam, A., Tutuka, C. S. A., Ostrouska, S., Blackburn, J. M., Behren, A., & Cebon, J. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00411 · Cited by 78
The Paradox of Cancer Immune Exclusion: Immune Oncology Next Frontier
Pai, S. I., Cesano, A., & Marincola, F. M. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_6 · Cited by 81
Singh, M. P., Sethuraman, S. N., Miller, C., Malayer, J. R., & Ranjan, A. (2020) · Theranostics · doi:10.7150/thno.49517 · Cited by 82
Budczies, J., Kirchner, M., Kluck, K., Kazdal, D. N., Glade, J., Allgäuer, M., Kriegsmann, M., Heußel, C. P., Herth, F. J. F., Winter, H., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1860586 · Cited by 80
Küçükköse, E., Heesters, B. A., Villaudy, J., Verheem, A., Cercel, M. G., van Hal, S., Boj, S. F., Rinkes, I. H. M. B., Punt, C. J. A., Roodhart, J. M. L., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005345 · Cited by 78
Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006947 · Cited by 81
Chibaya, L., DeMarco, K. D., Lusi, C. F., Kane, G. I., Brassil, M. L., Parikh, C. N., Murphy, K. C., Chowdhury, S. R., Li, J., Ma, B., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj9366 · Cited by 77
Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer
Meyers, D. E., Bryan, P., Banerji, S. O., & Morris, D. G. (2018) · Current Oncology · doi:10.3747/co.25.3976 · Cited by 76
Application of NanoString technologies in companion diagnostic development
Eastel, J. M., Lam, K. W., Lee, N. L., Lok, W. Y., Tsang, H. F., Pei, X. M., Chan, A. K. C., Cho, W. C. S., & Wong, S. C. C. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2019.1623672 · Cited by 74
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms
Wang, Y., Mohseni, M., Grauel, A., Diez, J. E., Guan, W., Liang, S., Choi, J. E., Pu, M., Chen, D., Laszewski, T., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-80999-x · Cited by 73
Immune profiles in primary squamous cell carcinoma of the head and neck
Saloura, V., Izumchenko, E., Zuo, Z., Bao, R., Korzinkin, M., Ozerov, I. V., Zhavoronkov, A. A., Sidransky, D., Bedi, A., Hoque, M. O., et al. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.06.032 · Cited by 74
Self-citationBiomarkers in Precision Cancer Immunotherapy: Promise and Challenges
McKean, W. B., Moser, J. C., Rimm, D. L., & Hu‐Lieskovan, S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280571 · Cited by 79
Scalera, S., Mazzotta, M., Corleone, G., Sperati, F., Terrenato, I., Krasniqi, E., Pizzuti, L., Barba, M., Vici, P., Gallo, E., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.010 · Cited by 80
Metadata
- Authors
- Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., Piha-Paul, S. A., Yearley, J., Seiwert, T. Y., Ribas, A., & McClanahan, T. K.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- University of Washington (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Chicago (US)
- University of California, Los Angeles (US)
- Corresponding author
- McClanahan, Terrill K.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-06-26
- Volume
- 127
- Issue
- 8
- Pages
- 2930-2940
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5531419
- OpenAlex
- W2655262992
- Cited by
- 3,788
- References
- 31
- Citations by year
- 2026: 358 · 2025: 391 · 2024: 518 · 2023: 551 · 2022: 608 · 2021: 512 · 2020: 400 · 2019: 263 · 2018: 159 · 2017: 24
- FWCI
- 101.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- interferon-gamma, anti-PD-1 therapy, pembrolizumab, predictive biomarkers, gene expression profiles, PD-L1 expression, immune checkpoint inhibitors, melanoma, head and neck squamous cell carcinoma, adaptive immune resistance, antigen presentation, chemokine expression
- MeSH terms
- Antineoplastic Agents, Biopsy, Carcinoma, Carcinoma, Non-Small-Cell Lung, Humans, Immune System, Immunohistochemistry, Interferon-gamma, Lung Neoplasms, Melanoma, Pilot Projects, ROC Curve, Skin Neoplasms, Stomach Neoplasms, Signal Transduction, Gene Expression Regulation, Neoplastic, Treatment Outcome, Sequence Analysis, RNA, Gene Expression Profiling, Tumor Microenvironment, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.